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Abstract
Background: Currently available vaccines against leptospirosis are of low efficacy, have an unacceptable
side-effect profile, do not induce long-term protection, and provide no cross-protection against the
different serovars of pathogenic leptospira. The current major focus in leptospirosis research is to
discover conserved protective antigens that may elicit longer-term protection against a broad range of
Leptospira. There is a need to screen vaccine candidate genes in the genome of Leptospira interrogans.
Results: Bioinformatics, comparative genomic hybridization (CGH) analysis and transcriptional analysis
were used to identify vaccine candidates in the genome of L. interrogans serovar Lai strain #56601. Of a
total of 4727 open reading frames (ORFs), 616 genes were predicted to encode surface-exposed proteins
by P-CLASSIFIER combined with signal peptide prediction, α-helix transmembrane topology prediction,
integral β-barrel outer membrane protein and lipoprotein prediction, as well as by retaining the genes
shared by the two sequenced L. interrogans genomes and by subtracting genes with human homologues. A
DNA microarray of L. interrogans strain #56601 was constructed for CGH analysis and transcriptome
analysis in vitro. Three hundred and seven differential genes were identified in ten pathogenic serovars by
CGH; 1427 genes had high transcriptional levels (Cy3 signal ≥ 342 and Cy5 signal ≥ 363.5, respectively).
There were 565 genes in the intersection between the set encoding surface-exposed proteins and the set
of 307 differential genes. The number of genes in the intersection between this set of 565 and the set of
1427 highly transcriptionally active genes was 226. These 226 genes were thus identified as putative vaccine
candidates. The proteins encoded by these genes are not only potentially surface-exposed in the
bacterium, but also conserved in two sequenced L. interrogans. Moreover, these genes are conserved
among ten epidemic serovars in China and have high transcriptional levels in vitro.
Conclusion: Of the 4727 ORFs in the genome of L. interrogans, 226 genes were identified as vaccine
candidates by bioinformatics, CGH and transcriptional analysis on the basis of the theory of reverse
vaccinology. The proteins encoded by these genes might be useful as vaccine candidates as well as for
diagnosis of leptospirosis.
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Background
Leptospirosis is a globally important zoonotic disease
caused by pathogenic Leptospira species[1]. Leptospires are
thin, helically coiled, motile bacteria, classified into 17
genomospecies (including the saprophyte Leptospira bifl-
exa and the pathogen Leptospira interrogans) on the basis of
DNA-DNA hybridization studies, or serologically classi-
fied into more than two hundred pathogenic serovars on
the basis of structural heterogeneity in the carbohydrate
component of the lipopolysaccharide[2,3]. Currently
available vaccines, based on inactivated whole bacteria or
membrane preparations from pathogenic leptospires, are
of low efficacy, have an unacceptable side-effect profile,
require annual booster immunizations and do not confer
cross-protective immunity against different serovars [4-6].
Because of these concerns, the current major focus in lept-
ospirosis research is to discover cross-species-conserved or
cross-serovar-conserved protective antigens that may elicit
longer-term protection against a broad range of Lept-
ospira[5,7]. New vaccine development strategies are thus
needed for preventing this zoonosis. Reverse vaccinology,
which based on the genomic approach, has been applied
to some bacteria, and novel vaccine candidate sequences
have been identified [8-11]. The genome projects of two
Leptospira  strains give us intensive knowledge on the
whole genome level [12-14]. Although many efforts have
been made to identify the surface-exposed proteins of
leptospires, finding perfect vaccine candidate antigens
that provide cross-protection against different serovars of
pathogenic L. interrogans still requires further work[7,15-
17].
In our current study, we identified 226 potential candi-
date vaccine genes against L. interrogans using  in silico
analysis, comparative genomic hybridization (CGH) and
transcriptional analysis, based on a genome-wide DNA
microarray comprising 3528 open reading frames (ORFs)
derived from the original annotation of L. interrogans
strain #56601. These candidate genes not only encode
surface-exposed proteins of L. interrogans strain #56601,
but also have high transcription levels in vitro. Moreover,
the proteins encoded by these genes are conserved in two
sequenced  L. interrogans and ten epidemic pathogenic
serovars in China.
Results
In silico analysis for identification of genes encoding 
surface-exposed proteins
In 4727 ORFs of L. interrogans strain #56601, 1282 pro-
teins were predicted to be surface-exposed using P-CLAS-
SIFIER, 654 proteins had signal peptides, 813 were
predicted to have no more than four α-helices with trans-
membrane topology, 96 were predicted to have β-barrel
topology implying that they are integral β-barrel outer
membrane proteins, and 158 were predicted have a lipo-
protein signal peptide using SpLiP. The number of genes
in the intersection between the set of surface-exposed pro-
teins identified by P-CLASSIFIER and the set of proteins
characterized by at least one of the four characteristic
topologies is 688. We calculated the similarity of proteins
between serovar Lai and serovar Copenhageni as well as
between serovar Lai and human (cut-off value: similarity
>70% and E value = 1e-10 for two serovars, E value = 1e-
10 for serovar Lai and human) using BLASTP. We found
3672 orthologs between the two serovars, and 605 pro-
teins that are similar in serovar Lai and human. Finally,
616 genes were yielded by the bioinformatics study by
retaining the orthologs between the two serovars and sub-
tracting the genes that were similar in serovar Lai and
human.
Comparative genomic hybridization
We prepared a gene chip microarray corresponding to the
complete genome sequence of L. interrogans strain
#56601. The chips were hybridized to labelled total DNA
extracted from strain Fiocruz L1–130 and ten pathogenic
serovars. On the basis of test hybridizations of strain
Fiocruz L1–130 vs. the reference sample, we considered
genes that gave hybridization ratios between 1.0 and 3.0
to be present in both strains and greater than 10.0 to be
absent from the test strain. Ambiguous values between 3.0
and 10.0 may have been due to highly divergent genes or
hybridization to paralogous genes. The CGH results
revealed that 307 genes of L. interrogans strain #56601
were absent or highly divergent in at least one strain
tested. After subtracting these 307 differential genes, we
were left with 565 genes, which not only encode presum-
ably surface-exposed proteins but also are conserved in
the ten pathogenic serovars.
Transcriptome analysis
Microarray analysis of the mRNA extracted from in vitro
grown leptospires revealed that the fluorescence signals of
Cy3 and Cy5 ranged from 10.5 to 51,707 (see Figure 1);
1427 genes were expressed above the median level (Cy3
signal ≥ 342 and Cy5 signal ≥ 363.5) in the microarray
and therefore as genes with high transcriptional levels.
The intersection between the sets of 565 and 1427 genes
contained 226 genes. Among them, 8.0% (18/226) were
located extracellularly, 53.1% (120/226) in the outer
membrane, 16.4% (37/226) in the periplasmic space and
22.6% (51/226) in the inner membrane according to pre-
dictions. These vaccine candidates were classified further
according their gene names and clusters of orthologous
groups (COGs) [18,19](Table 1, 2, 3, 4); 60.6% (137/
226) of the candidates had COG annotations.
Discussion
Vaccines composed of whole cells or outer membrane
envelope are available in some countries to preventBMC Genomics 2006, 7:293 http://www.biomedcentral.com/1471-2164/7/293
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human leptospirosis, and clinical trials have been
reported [20-23]. In view of their disadvantages, espe-
cially their inability to elicit longer-term protection
against different serovars of pathogenic leptospires, efforts
have been focused on developing subunit vaccines[24].
During recent years, Hap1[25] (also known as
LipL32[26]), LipL41, OmpL1[27] and Lig[28,29] proteins
have been identified as promising vaccine candidates for
preclinical trials.
The availability of complete genome sequence informa-
tion for many pathogens and the development of sophis-
ticated computer programs have led to a new paradigm in
vaccine development. Now it is possible to screen poten-
tial vaccine candidate genes in a reverse manner starting
from the genome. This reverse vaccinology was first
applied to MenB[30] and is now applied routinely in vac-
cine development, as in the search for vaccines against S.
pneumoniae, Streptococcus agalactiae, Staphylococcus aureus,
Porphyromonas gingivalis, Chlamydia pneumoniae and other
microorganisms[10]. Bioinformatics analysis is the first
important strategy of reverse vaccinology. Gram-negative
bacteria have five subcellular location sites: cytoplasm,
inner membrane, outer membrane, periplasm and extra-
cellular space. The surface-exposed proteins, i.e. those
located in sites other than the cytoplasm, are the most
suitable vaccine candidates because they are more suscep-
tible to antibody recognition and can therefore elicit pro-
tective immune responses. Many sophisticated computer
programs have been developed to predict the subcellular
locations of putative proteins in the whole genome [31-
Table 1: The result of vaccine candidates according to localization sites: extracellular
gene Cy3 signal Cy5 signal COG product
LA0074 402.2 574.7 - hypothetical protein
LA0322 1,118 760.5 - hypothetical protein
LA0444 1,699 1,024 COG1196D 
COG4254S
hypothetical protein
LA0587 3,246 2,998 COG1075R Lactonizing lipase
LA0617 672 487.5 - hypothetical protein
LA1433 1,946 1,552 - hypothetical protein
LA1508 559.2 853 - putative outermembrane protein
LA1569 755.3 391.3 COG5651N putative lipoprotein
LA2471 354.5 572.5 COG0457R putative outermembrane protein
LA2823 1,466 884 - putative lipoprotein
LA2975 478.8 454.2 - hypothetical protein
LA2992 663.8 535.3 COG0419L hypothetical protein
LA3210 410.7 847.7 - hypothetical protein
LA3338 899.8 795.8 - putative lipoprotein
LA3394 392.3 652 - hypothetical protein
LA3779 374.8 431.7 - hypothetical protein
LA3848 395.5 368.8 - putative lipoprotein
LB225 798 1,069 - hypothetical protein
Identification of highly expressed genes in L. interrogans by  microarray Figure 1
Identification of highly expressed genes in L. interrogans by 
microarray. Bacteria were grown in EMJH medium at 37°C 
and were collected when the culture reached mid-exponen-
tial-phase. RNA was purified and labelled with either Cy3 or 
Cy5 and hybridized with the microarray of L. interrogans 
strain #56601 (3528 genes). Transcription analysis revealed 
that 1427 genes were highly expressed (cy3 signal ≥ 342 and 
cy5 signal ≥ 363.5).BMC Genomics 2006, 7:293 http://www.biomedcentral.com/1471-2164/7/293
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Table 2: The result of vaccine candidates according to localization sites: outermembrane
gene Cy3 signal Cy5 signal COG product
LA0049 471 478.2 COG0840NT COG2202T aerotaxis sensor receptor, flavoprotein
LA0099 1,081 853.5 - hypothetical protein
LA0166 2,149 1,113 COG1196D hypothetical protein
LA0178 1,224 953.8 COG0706U 60Kd inner membrane protein
LA0241 554.5 905.7 COG1999R SCO1/SenC family protein
LA0253 755.8 559.2 COG2849S hypothetical protein
LA0272 462.2 734.8 - hypothetical protein
LA0301 787 771.8 COG2885M outer membrane protein OmpA family
LA0330 554 397.3 COG2366R Penicillin G acylase precursor
LA0339 1,060 1,185 COG0584C Glycerophosphoryl diester phosphodiesterase
LA0365 1,290 1,959 - hypothetical protein
LA0370 720.7 952.8 - hypothetical protein
LA0378 692.5 560.3 COG0457R TPR-repeat-containing proteins
LA0379 1,134 957 - hypothetical protein
LA0410 3,451 3,604 COG2834M hypothetical protein
LA0423 553 712.8 COG2931Q hypothetical protein
LA0505 6,317 7,727 COG1409R probable glycosyl hydrolase
LA0532 736.5 684.7 - hypothetical protein
LA0568 434.8 435.3 COG2067I hypothetical protein
LA0635 1,131 712.8 - S-layer-like array protein
LA0678 973.3 952.5 COG0840NT Methyl-accepting chemotaxis protein mcpB
LA0811 478.8 770.5 - hypothetical protein
LA0818 481.3 946.8 - hypothetical protein
LA0878 886.7 555.7 COG0266L DshA protein
LA0940 1,467 1,026 - hypothetical protein
LA0957 2,798 1,542 COG1538MU outer membrane efflux protein
LA1009 764.8 887.7 COG5009M Penicillin-binding protein 1A
LA1010 1,124 829 - putative outermembrane protein
LA1087 376.5 536 - hypothetical protein
LA1099 2,388 1,500 COG3103T hypothetical protein
LA1100 2,901 2,796 COG1538MU outer membrane efflux protein
LA1161 474.2 403 COG2067I long-chain fatty acid transport protein
LA1174 615 423 COG0834ET amino acid ABC transporter, periplasmic amino acid-binding protein
LA1192 616.3 545.3 - putative outermembrane protein
LA1404 1,377 977 - putative outermembrane protein
LA1412 1,034 640.3 - hypothetical protein
LA1495 1,920 2,172 - putative outermembrane protein
LA1501 558.2 545.7 COG4775M COG5009M hypothetical protein
LA1507 1,615 1,747 - hypothetical protein
LA1690 744.7 471.7 COG0449M hypothetical protein
LA1733 1,418 1,557 - hypothetical protein
LA1912 873.8 745 - putative outermembrane protein
LA1917 595.5 535.3 - hypothetical protein
LA1931 941.5 1,540 - putative outermembrane protein
LA1987 909.3 994.5 - putative outermembrane protein
LA1996 556.8 674 - hypothetical protein
LA2024 2,594 2,079 - hypothetical protein
LA2063 1,463 1,967 - hypothetical protein
LA2094 548.2 380.3 COG1716T FHA-domain containing protein
LA2126 1,223 979.7 COG0616OU Putative signal peptide peptidase sppA
LA2215 1,045 679.2 COG1196D COG1360N Chemotaxis motB protein
LA2238 420 464.7 COG0726G polysaccharide deacetylase
LA2266 367.3 364.5 - putative outermembrane protein
LA2267 886.2 1,542 COG0457R putative outermembrane protein
LA2268 971.7 1,074 - putative outermembrane protein
LA2295 4,445 6,689 COG0532J COG4254S LipL45 protein
LA2318 813.2 673.8 COG4775M Predicted outer membrane protein
LA2368 347.8 585 COG1555L COG3156U 
COG0477GEPR COG0075E
type II secretion pathway related protein etpK-like protein
LA2375 1,255 2,047 COG1450NU General secretory pathway protein DBMC Genomics 2006, 7:293 http://www.biomedcentral.com/1471-2164/7/293
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LA2377 377.5 418 COG0739M peptidase, M23/M37 family protein
LA2395 847.3 1,736 COG2815S putative outermembrane protein
LA2413 540.7 381.2 COG0791M Probable lipoprotein nlpC precursor
LA2464 362 435.7 COG3225N gliding motility protein GldG
LA2468 3,653 6,205 COG1196D hypothetical protein
LA2510 1,230 846 COG1452M hypothetical protein
LA2537 1,329 1,304 - hypothetical protein
LA2538 624.2 606.5 - hypothetical protein
LA2612 532.8 574 COG3190N flagellar protein required for flagellar formation
LA2617 656.5 697.8 - hypothetical protein
LA2656 1,128 637.2 COG2968S hypothetical protein
LA2664 905.3 867.8 COG1706N flagellar P-ring protein precursor
LA2672 662.3 1,116 - hypothetical protein
LA2741 1,649 916.7 - hypothetical protein
LA2742 814.8 524.2 - hypothetical protein
LA2755 4,175 2,808 COG0768M probable penicillin-binding protein
LA2757 1,213 1,270 COG1792M rod shape-determining protein mreC
LA2800 665 1,591 - hypothetical protein
LA2818 681.7 440.8 - hypothetical protein
LA2857 506.7 516.5 COG0596R Predicted hydrolase or acyltransferase, alpha/beta hydrolase superfamily
LA2949 407.5 460 COG0265O heat shock protein, HtrA1
LA3069 1,221 786.3 - hypothetical protein
LA3091 995.5 879.7 - hypothetical protein
LA3118 771.7 1,239 COG0466O hypothetical protein
LA3149 608.3 421.8 COG1629P Hemin receptor
LA3165 749.2 454.7 COG4642S conserved hypothetical protein with MORN repeat
LA3353 432.2 698.2 - hypothetical protein
LA3403 391.3 388.8 - hypothetical protein
LA3434 724.7 625.7 COG0860M N-acetylmuramoyl-L-alanine amidase
LA3440 915.5 864.3 COG0237H hypothetical protein
LA3468 618 584.8 COG1629P probable TonB-dependent receptor
LA3469 658.2 685.7 COG3487P iron-reglulated protein A
LA3506 1,407 1,266 COG0840NT Methyl-accepting chemotaxis protein
LA3552 1,652 2,900 - hypothetical protein
LA3632 1,028 1,337 COG1413C PBS lyase HEAT-like repeat containing protein
LA3681 463.5 459 - phage-related-like protein
LA3744 1,318 840.2 - hypothetical protein
LA3862 537.3 761.3 COG0532J hypothetical protein
LA3872 385.3 648.8 COG0616OU Putative signal peptide peptidase sppA
LA3938 589 1,026 COG0457R hypothetical protein
LA3970 532.7 398.5 - hypothetical protein
LA4070 9,764 5,630 - hypothetical protein
LA4212 1,678 1,684 - hypothetical protein
LA4227 2,465 1,953 COG5621R hypothetical protein
LA4232 509.3 612.2 COG2982M hypothetical protein
LA4261 485.7 612.5 COG0451MG UDP-glucose 4-epimerase
LA4263 1,012 1,290 - hypothetical protein
LA4285 726.3 791.2 COG3858R hypothetical protein
LA4341 1,009 1,146 COG0739M Peptidase family M23/M37
LB018 1,549 1,589 COG1635H hypothetical protein
LB025 371.8 382.5 - hypothetical protein
LB050 344 533.3 - hypothetical protein
LB056 443.5 523.8 COG0457R TPR-repeat-containing protein
LB061 550.2 769.7 COG3211R hypothetical protein
LB191 344.3 410 COG1629P COG4771P putative TonB-dependent outer membrane receptor protein
LB199 917.3 925.2 COG1629P putative outermembrane protein
LB258 552.5 1,082 COG4870O Cysteine protease
LB277 1,634 984.3 - hypothetical protein
LB279 1,115 804.3 COG1629P hypothetical protein
LB328 1,591 2,672 COG1360N COG2885M outer membrane protein OmpA
LB362 1,246 7,69 - hypothetical protein
Table 2: The result of vaccine candidates according to localization sites: outermembrane (Continued)BMC Genomics 2006, 7:293 http://www.biomedcentral.com/1471-2164/7/293
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Table 3: The result of vaccine candidates according to localization sites: periplasmic
gene Cy3 signal Cy5 signal COG product
LA0430 2,614 2,094 COG1830G hypothetical protein
LA0011 1472.2 2164 - putative lipoprotein
LA0093 963.2 539.3 - hypothetical protein
LA0107 476 466.3 - hypothetical protein
LA0222 9,873 18,863 COG2885M outer membrane protein OmpA family
LA0312 526.2 366.7 COG0739M M23/M37 family protein
LA0413 505.3 544.2 - hypothetical protein
LA0494 551 1,165 - hypothetical protein
LA0569 404.2 366.3 - hypothetical protein
LA0616 8,877 7,462 COG0457R outer membrane lipoprotein lipL41
LA1118 610.2 614.3 - putative outermembrane protein
LA1136 636.5 1,301 COG2834M hypothetical protein
LA1155 534.3 563.8 COG1613P sulfate-binding protein precursor
LA1312 1,514 1,070 - hypothetical protein
LA1448 1,090 1,857 COG1464P putative outermembrane protein
LA1998 676 700.8 COG0726G polysaccharide deacetylase
LA2023 622 405 COG2010C cytochrome c
LA2208 2,252 2,334 COG3858R hypothetical protein
LA2277 609.5 391.3 - hypothetical protein
LA2316 633.3 707.2 - putative outermembrane protein
LA2372 1,427 2,257 COG2165NU General secretory pathway protein G
LA2531 1,177 894.5 COG1196D hypothetical protein
LA2637 51,707 37,602 - LipL32 protein
LA2748 714.5 537.3 COG1613P Sulfate-binding protein precursor
LA2820 691.3 525.5 - hypothetical protein
LA2950 373.8 661 COG0265O HtrA2
LA2993 349 433.8 - hypothetical protein
LA3507 1,360 721.7 COG2010C putative cytochrome c
LA3535 541.2 659.8 - hypothetical protein
LA3571 607.2 492.8 COG2010C putative cytochrome c
LA3576 595.8 594.5 COG1360N flagellar motor protein
LA3780 1,365 1,432 - hypothetical protein
LA3839 664 618.3 COG1881R Phosphatidylethanolamine-binding family protein
LA3944 507.3 595.2 - hypothetical protein
LA4262 355 515.8 - hypothetical protein
LB047 506.3 2,137 COG2849S hypothetical protein
LB098 735.5 507.3 COG0726G Predicted xylanase/chitin deacetilaseBMC Genomics 2006, 7:293 http://www.biomedcentral.com/1471-2164/7/293
Page 7 of 12
(page number not for citation purposes)
Table 4: The result of vaccine candidates according to localization sites: innermembrane
gene Cy3 signal Cy5 signal COG product
LA0238 662.5 433.2 COG1612O cytochrome-c oxidase assembly factor ctaA
LA0250 651.2 738.8 COG4956R TRAM family protein
LA0314 577.2 368 COG0168P Trk system potassium uptake protein trkH
LA0550 1,353 886.5 COG0841V NolG efflux transporter
LA0639 858.2 469.7 - hypothetical protein
LA0650 870.7 628 COG0705R Rhomboid family protein
LA0680 530.2 707.5 COG0004P hypothetical protein
LA0960 760.7 452 - hypothetical protein
LA1056 702.7 607.8 COG0840NT hypothetical protein
LA1143 4,027 4,074 COG0341U Preprotein translocase subunit SecF
LA1191 1,014 790.7 COG0840NT Methyl-accepting chemotaxis protein
LA1283 902.2 1,162 COG0845M hypothetical protein
LA1284 415.7 543 COG4591M Lipoprotein releasing system transmembrane protein lolC
LA1321 374.8 860.8 COG4232OC thiol:disulfide interchange protein DsbD
LA1397 722.8 672.3 COG1033R putative Protein export membrane protein SecD/SecF
LA1435 612.2 524.3 COG0392S hypothetical protein
LA1451 415.2 435.2 COG1183I Phosphatidylglycerophosphate synthase
LA1471 3,360 7,809 COG3808C Pyrophosphate-energized vacuolar membrane proton pump
LA1477 566.7 436.8 COG1519M 3-deoxy-D-manno-octulosonic-acid transferase
LA1535 521.5 685.5 - hypothetical protein
LA1554 498.7 398.2 COG1502I hypothetical protein
LA1695 4,493 2,360 - CrcB-like protein
LA1958 2,663 1,551 COG0526OC putative outermembrane protein
LA1979 483.8 657.8 COG0463M Putative glycosyl transferase
LA1982 342.5 452 COG3307M hypothetical protein
LA2050 411.3 848.8 COG0707M UDP-N-acetylglucosamine:LPS N-acetylglucosamine transferase
LA2250 10,742 9,624 - Nuclease S1
LA2275 1,415 1,071 COG0586S dedA protein
LA2320 1,319 1,496 COG0811U biopolymer transport protein, putative
LA2604 464.3 448.7 - hypothetical protein
LA2737 3,813 2,157 COG0204I putative acyltransferase
LA2891 5,229 3,140 COG1055P hypothetical protein
LA3072 1,970 1,665 COG0477GEPR hypothetical protein
LA3110 1,262 2,371 COG2156P potassium-transporting ATPase, C chain
LA3146 877 523.2 COG2076P hypothetical protein
LA3577 1,618 1,198 COG1291N motility protein A
LA3586 2,348 1,746 COG4270S hypothetical protein
LA3754 667.3 449.7 COG0681U Signal peptidase I
LA3777 497.3 539 COG0239D Protein crcB homolog
LA3806 2,116 2,869 COG0004P Probable ammonium transporter
LA3916 5,518 5,510 - hypothetical protein
LA3926 967.8 1,802 COG0841V transmembrane efflux pump protein
LA4062 1,326 2,138 - hypothetical protein
LA4154 638.7 759 COG3225N hypothetical protein
LA4155 1,140 1,015 COG1277R probable permease of ABC transporter
LA4172 411 392.5 - hypothetical protein
LA4228 559.5 627.8 COG4174R Dipeptide transport system permease protein dppB
LA4233 409 985.7 COG1172G hypothetical protein
LA4269 1,907 2,240 COG2207K COG0477GEPR transcriptional regulator, AraC family
LB174 2,150 3,440 COG0501O heat shock protein HtpX
LB281 5,026 2,708 COG0811U transport protein ExbBBMC Genomics 2006, 7:293 http://www.biomedcentral.com/1471-2164/7/293
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33]. Analyzing the gene transcription profile using DNA
microarrays provides a second vaccine candidate selection
strategy in reverse vaccinology. A gene having a fluores-
cent signal above the median value corresponds to an
expression level higher than 5–10 mRNA copies per
genome[34]. Those highly expressed genes could be
potential vaccine candidates[34]. Finally, other
approaches such as proteomic technology can be used to
screen vaccine candidates. Using combined these strate-
gies, genes encoding potential vaccine antigens can even-
tually be identified.
In our preliminary selection, all genes in L. interrogans
strain #56601 were searched using P-CLASSIFIER, a sys-
tem for predicting the subcellular locations of proteins on
the basis of amino acid subalphabets and a combination
of multiple support vector machines[33]. Moreover, four
topologies were predicted by the corresponding pro-
grams. Proteins predicted to be surface-exposed and hav-
ing any of these four topologies were screened as
preliminary vaccine candidates. All proteins with more
than four predicted transmembrane spanning regions
were removed from the list of candidates, not only
because they are likely to be completely embedded in the
cell membrane and therefore inaccessible to antibodies,
but also because they are difficult to express in E. coli[34].
We retained the genes shared by the two sequenced sero-
vars and subtracted genes that had human homologues.
The reason we subtracted human homologues is they are
likely to cause problems of autoimmunity[35]. Finally, we
narrowed the list of vaccine candidates to 616 genes in the
genome of L. interrogans strain #56601.
In order to explore vaccine candidates that could generate
cross-protection against the diverse serovars of lepto-
spires, we applied CGH to identify genes that are con-
served among the ten pathogenic strains involved in most
infections[36]. This approach allowed us to refine the vac-
cine candidate shortlist further by eliminating antigens
that were not conserved among these serovars. The 565
vaccine candidates not only presumably surface-exposed
but also conserved among the ten prevalent serovars in
China were identified as the result of this approach.
Transcriptome analysis was performed using DNA micro-
arrays of L. interrogans in order to assess the transcription
levels of all genes in the genome. A graph of the signal
obtained for each gene gave a diagonal distribution
reflecting the expression level of that gene. After subtract-
ing genes with transcriptional levels below the median,
we were left with 226 genes as vaccine candidates.
Applying the theory of reverse vaccinology, 226 genes had
been identified as potential vaccine candidates against L.
interrogans combined bioinformatics, CGH and transcrip-
tional analysis. Among them, 60.6% (137/226) have
COG annotations; thus, nearly 40% either have an
unknown function or have no COG annotation. This
group of gene products offers great promise as it com-
prises a pool of previously unexploited vaccine targets. To
evaluate our results, we compared our candidates with
those identified by others. Gamberini et al. (2005) found
approximately 20% potential surface proteins using in sil-
ico  approach, and sixteen proteins were recognized by
antibodies present in human sera[15]. However, only
three of them (LA0222, LA2637 and LA2741) appear in
our final set. This is not unexpected, since 206 genes
encoding hypothetical or unknown proteins were selected
from approximately 20% of the genome for cloning and
expression. Nally et al. (2005) characterized 32 proteins
in outer membrane vesicles of L. interrogans serovar
Copenhageni by two-dimensional gel electrophoresis,
including previously-described outer membrane proteins
(OMPs); in addition, unknown, hypothetical and puta-
tive OMPs were also identified[17]. Interestingly, only
two proteins (LA0222 and LA2637) are represented
among the sixteen proteins found by Gamberini and co-
workers. There is an overlap of eight genes between our
result and that of Nally et al. (2005) (LA0222, LA0505,
LA0616, LA1495, LA2024, LA2295, LA2637 and
LA3091). The reasons responsible for the discrepancies
among the results may be due to differing methodologies.
Genomics, transcriptional profiling and proteomics have
emerged in the post genomic era with potential to speed
up the vaccine discovery research process. It should be
pointed out that those methods have their respective
advantages and limitations, and can be complementally
utilized in the development of the novel vaccines.
Genomics involves the use of various softwares to predict
sublocalization of proteins. However, some algorithms
have limited accuracy. Although transcriptome analysis
uses gene chip array to measure gene expression but suf-
fers from the fact that mRNA levels may not reflect protein
levels. Expression of a transcribed gene may be regulated
at the level of translation. It is believed that the proteome
maps of microorganisms are important to understand cel-
lular status at the protein level, which cannot be deci-
phered from genome or transcriptome analysis[37].
Proteomics of outer membrane can rapidly identify
almost all proteins in outer membrane. However, some of
the proteins identified in membrane preparations are in
fact typical cytoplasmic proteins[10,38]. Moreover, one of
the major disadvantages of subproteomic studies by 2-D
gel electrophoresis and mass spectrometry is the potential
for contamination via leaky fractionation or lysis[39].
Nally et al. (2005) also revealed that outer membrane ves-
icles contain small amounts of inner membrane or cyto-
plasmic proteins in their proteomic study[17]. It is worth
mentioning here that mainly surface-exposed proteins
such as LipL32 (LA2637)[26,40], LipL41BMC Genomics 2006, 7:293 http://www.biomedcentral.com/1471-2164/7/293
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(LA0616)[27,40], LipL45 (LA2295)[41] and LipL21
(LA0011)[42] have higher transcriptional levels in our
results; this suggests that the genes with higher transcrip-
tional levels identified in our current research may be
preferable for development as vaccine candidates.
This is the first time that CGH and transcription analysis
have been used to identify potential candidates for vac-
cines against L. interrogans. Our present work corroborates
previous studies, showing the advantages of reverse vacci-
nology[8,11]. The next step following our present
research is to verify whether the selected vaccine candi-
dates are surface-exposed and to evaluate the protective
activities of these proteins. Such studies will lead to the
development of safe and effective new vaccines against
leptospirosis in the future.
Conclusion
We have performed high-throughput in silico and microar-
ray-based processes that are useful for determining poten-
tial vaccine candidates against leptospirosis. In total, 226
genes were identified in the genome of L. interrogans sero-
var Lai type strain #56601 using bioinformatics, CGH and
transcriptional analysis. The proteins encoded by these
genes are not only potentially surface-exposed in the bac-
terium, but also conserved in two sequenced L. interro-
gans. Moreover, these genes are conserved among ten
epidemic serovars in China and have high transcriptional
levels in vitro. These proteins might therefore be useful for
vaccine candidates as well as for the diagnosis of lept-
ospirosis. Further research, including verification that
these vaccine candidates are surface-exposed and evalua-
tion their protective activities, will aid in the study of vac-
cines against leptospirosis in the future.
Methods
Bacteria strains and growth condition
Ten strains of L. interrogans were used in this study (Table
5). All the strains were obtained from the Institute for
Infectious Disease Control and Prevention (IIDC), Bei-
jing, China. Leptospires were maintained by serial pas-
sages in guinea pigs for preservation of virulence and were
cultured in liquid Ellinghausen-McCullough-Johnson-
Harris (EMJH) medium at 28°C or 37°C with shaking
under aerobic conditions. Culture conditions were then
developed to ensure that only mid-exponential-phase
bacterial cultures at a mean density of 106/ml were used
in further experimentation. The cells were harvested by
centrifugation at 10,000 g for 10 min at 4°C.
The L. interrogans serogroup Icterohaemorrhagiae serovar
Lai type strain #56601 (strain Lai) was used to construct
the DNA microarray. The genomic DNA of strain Fiocruz
L1–130 was kindly provided by the Centro de Pesquisas
Goncalo Moniz.
In silico analysis
Genes and protein data for human and for the sequenced
L. interrogans (serovar Lai and serovar Copenhageni) were
downloaded from NCBI. P-CLASSIFIER[33] was applied
to predict the subcellular locations of proteins in L. inter-
rogans strain #56601. Signal peptide prediction was car-
ried out using SignalP 3.0[43]. α-Helix transmembrane
topology prediction was carried out using TMHMM[44].
BOMP was used to predict β-barrel outer membrane pro-
teins[45]. Putative lipoproteins were predicted by
SpLiP[46]. To identify proteins orthologous between sero-
var Lai and serovar Copenhageni as well as between sero-
var Lai and human, all predicted proteins were searched
against each other locally using BLASTP[47].
Comparative genomic hybridization
DNA microarrays of L. interrogans strain #56601 consist-
ing of 3528 annotated ORFs longer than 250bp were pre-
pared as previously described [48]. The genomic DNA of
L. interrogans strain #56601 was used for reference in the
double-fluorescence hybridization, and the genomic DNA
of strain Fiocruz L1–130 was used as a control. A CGH
microarray analysis of strain Lai and strain Fiocruz L1–
130 was performed first. The qualified threshold deter-
mined in this control experiment was used to identify
gene deletions in other strains. Reference or test DNA was
fluorescently labelled through direct incorporation of
Cy3-dCTP or Cy5-dCTP (Amersham Pharmacia Biotech)
respectively by a randomly primed polymerization reac-
tion. Unincorporated nucleotides and random primers
were removed using QIAquick Nucleotide Removal col-
umns (QIAGEN) according to the manufacturer's instruc-
tions.
Hybridizations were conducted in a hybridization cham-
ber at 42°C overnight. Slides were washed at 55°C with 1
× SSC containing 0.2% SDS for 10 min and then at 55°C
with 0.1 × SSC containing 0.2% SDS for 20 min and
finally at room temperature with 0.1 × SSC for 3 min.
Competitive hybridization was performed twice for each
strain. In the first experiment, L. interrogans strain #56601
reference DNA and the sample DNA were labelled with
Cy3 and Cy5, respectively. In the second hybridization,
the dyes for labelling were interchanged.
Microarrays were scanned using a Chipreader laser scan-
ner GenePix 4000B AXON (Axon Instruments, Union
City, CA) according to the manufacturer's recommenda-
tions. Spot quantification, signal normalization and data
visualization were performed using the programs Gene-
Spring 5.0.2 (Silicon Genetics) and Microsoft Excel.
Transcriptome analysis
L. interrogans was grown in EMJH medium at 37°C under
aerobic conditions for transcriptome analysis. Only mid-BMC Genomics 2006, 7:293 http://www.biomedcentral.com/1471-2164/7/293
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log-phase cultures at a mean density of 106/ml in 100 ml
were used in transcriptional experiments.
Total RNA was isolated from leptospires using Trizol rea-
gent (Invitrogen) according to the manufacturer's proto-
col. Contaminating DNA was digested with RQ1 RNase-
free DNase (Promega Corp.). The treated RNA was puri-
fied with a QIAGEN RNeasy Kit (QIAGEN).
RNA (10 µg) was labelled with Cy3 by reverse transcrip-
tion using Superscript α (Invitrogen). Unincorporated dye
was removed using a QIAquick Nucleotide Removal Kit
(QIAGEN) as specified in the manufacturer's protocol.
Samples were hybridized under cover slides to the micro-
array slides overnight at 42°C, and then washed as usual.
The hybridization slides were processed by Tiffsplit (Agi-
lent) and data were further analyzed using Genespring
software 5.0.2 and normalized using mean values com-
bined with Microsoft Excel software. Microarrays were
used to assay relative RNA abundance. Flagged spots or
SN<2 spots were excluded for intrachip and interchip
reproducibility analysis. We calculated the coefficients of
three spots in same chip for each gene to estimate intrac-
hip reproducibility using Microsoft Excel. The signal val-
ues from the experiments represent average mRNA
abundances. As in the CGH experiments, the dyes for
labelling Cy3 and Cy5 were interchanged in the second
hybridization.
Figure 2 is a scheme of the procedure we used to identify
the vaccine candidates as described above (the numbers in
parentheses are the results after the corresponding proce-
dure step).
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